Articoli di riviste sul tema "PT Indofarma"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "PT Indofarma".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.
Paramesti, Aswini, and Yugih Setyanto. "Strategi Komunikasi PT Indofarma Tbk dalam Membangun Kepercayaan Konsumen di Masa Pandemi." Kiwari 1, no. 1 (2022): 62. http://dx.doi.org/10.24912/ki.v1i1.15508.
Testo completoWahida Basri, Nur, Muh Rum, and Andi Rustam. "Comparison of Financial Performance in Pharmaceutical Industry Companies." Golden Ratio of Finance Management 4, no. 2 (2024): 226–41. http://dx.doi.org/10.52970/grfm.v4i2.459.
Testo completoSulistyani, Tri, and Neneng Tita Amalya. "Analysis of Financial Performance in Pharmaceutical Industry Sub-Sector Companies in Indonesia for the 2020 – 2022 Period." Transforma Jurnal Manajemen 2, no. 2 (2024): 52–64. http://dx.doi.org/10.56457/tjm.v2i2.128.
Testo completoPrihatiningrum, Nadia, and Lalu Husni. "Implementasi Penerapan Upah Minimum Kota Mataram Terhadap Pekerja Pada PT. Indofarma Global Medika." Private Law 4, no. 1 (2024): 139–49. https://doi.org/10.29303/prlw.v4i1.3928.
Testo completoAtiyah Kirana Ropidah and Diana Wiyanti. "Implementasi GCG PT. Indofarma Terkait Kasus Fraud Berdasarkan Permen BUMN No. Per-2/MBU/2023." Bandung Conference Series: Law Studies 5, no. 1 (2025): 233–42. https://doi.org/10.29313/bcsls.v5i1.15996.
Testo completoKurniati, Eling Ri, and Tryan Adhi Nugroho. "ANALISIS KINERJA KEUANGAN PT. KIMIA FARMA TBK DENGAN PT. INDOFARMA TBK SEBELUM PANDEMI DAN PADA SAAT PANDEMI COVID-19." Medikonis 13, no. 1 (2022): 20–28. http://dx.doi.org/10.52659/medikonis.v13i1.48.
Testo completoAviariska Primaning Happy. "Kepastian Hukum Dari Akta Keputusan Hasil e-RUPS Studi Kasus pada PT. Indofarma Tbk Tahun Buku 2019." Jurnal Akta Notaris 3, no. 2 (2024): 148–59. https://doi.org/10.56444/aktanotaris.v3i2.2154.
Testo completoDeni, Muhammad. "Pengaruh Etos Kerja Terhadap Kinerja Karyawan PT Indofarma Global Medika Cabang Palembang." Jurnal Manajemen Kompeten 4, no. 2 (2022): 56. http://dx.doi.org/10.51877/mnjm.v4i2.207.
Testo completoAwalya, Nabila, Yusnizal Firdaus, and Marieska Lupikawaty. "Analisis Rasio Profitabilitas Untuk Menilai Kinerja Keuangan pada PT Indofarma Tbk." Jurnal Terapan Ilmu Ekonomi, Manajemen dan Bisnis 2, no. 3 (2022): 127–34. https://doi.org/10.5281/zenodo.7473285.
Testo completoHandayani, Lovinta Valentina, and Mohamad Heykal. "Analisis dan Penilaian Bisnis Perusahaan BUMN di Industri Farmasi: Studi Kasus Kimia Farma dan Indofarma Tahun 2006-2008." Binus Business Review 3, no. 1 (2012): 155. http://dx.doi.org/10.21512/bbr.v3i1.1291.
Testo completoJunaedi, Junaedi. "PENGARUH CURRENT RATIO, DEBT TO EQUITY RATIO DAN TOTAL ASSET TURNOVER TERHADAP RETURN ON ASSET STUDI PADA PT. INDOFARMA Tbk YANG TERDAFTAR DI BURSA EFEK INDONESIA PERIODE 2015-2019." EKONOMI BISNIS 26, no. 2 (2020): 358–66. http://dx.doi.org/10.33592/jeb.v26i2.1045.
Testo completoWidyastuti, Indriyana, and Saptani Rahayu. "Akurasi Potensi Memprediksi Kebangkrutan Metode Altman Z-Score Dan Metode Ohlson O-Score." ProBank 3, no. 2 (2018): 1–7. http://dx.doi.org/10.36587/probank.v3i2.369.
Testo completoWidyastuti, Indriyana, and Saptani Rahayu. "Akurasi Potensi Memprediksi Kebangkrutan Metode Altman Z-Score Dan Metode Ohlson O-Score." ProBank 3, no. 2 (2018): 1–7. http://dx.doi.org/10.36587/probank.v3i2.369.
Testo completoMuna Jihan, Lintang Woro, and Risma Ajeng. "Analisis Selisih Nilai Tukar dan Transaksi Mata Uang Asing Pada PT Indofarma Tbk dan Entitas Anak." Jurnal Kendali Akuntansi 2, no. 1 (2023): 189–200. https://doi.org/10.59581/jka-widyakarya.v2i1.2045.
Testo completoNuha, Muhammad Ulin. "Analisis Kinerja Perusahaan Berbasis Balance Scorecard." Jurnal Akuntansi, Manajemen dan Perbankan Syariah 2, no. 3 (2022): 1–13. https://doi.org/10.32699/jamasy.v2i3.2822.
Testo completoHamida, Wulan, Ine Mayasari, Banter Laksana, and Dadang Hermawan. "Analysis of Optimal Capital Structure in the Pharmaceutical Industry Companies Listed on the Indonesia Stock Exchange." Indonesian Journal of Economics and Management 3, no. 1 (2022): 61–69. http://dx.doi.org/10.35313/ijem.v3i1.3117.
Testo completoAzzahra, Shafira, Sifa Nuraeni, Risna Haryati, Ruli Mochammad Chaerudin, and Tatiek Ekawati Permana. "ANALISIS KINERJA RASIO PROFITABILITAS PADA PERUSAHAAN MANUFAKTUR SEKTOR FARMASI YANG TERDAFTAR DI BURSA EFEK INDONESIA TAHUN 2019-2022." JURNAL EKONOMI BISNIS DAN MANAJEMEN (EKO-BISMA) 3, no. 2 (2024): 275–84. https://doi.org/10.58268/eb.v3i2.119.
Testo completoIsmail, Rizky. "Analisis Rasio Keuangan Untuk Menilai Kinerja Keuangan Perusahaan Kimia Farma Tbk dan PT Indofarma Tbk Periode waktu 1 Tahun." J-AKSI : JURNAL AKUNTANSI DAN SISTEM INFORMASI 4, no. 1 (2023): 1–7. http://dx.doi.org/10.31949/jaksi.v4i1.3026.
Testo completoPudjiani, Meilina, Yusman Syaukat, and Tony Irawan. "Optimum Portfolio Analysis of Black-Litterman Model in The Indonesian Stock Exchange on Consumer Goods Industrial Sector." Winners 21, no. 1 (2020): 27. http://dx.doi.org/10.21512/tw.v21i1.5954.
Testo completoPrayoga, Dwiputra Pangestu, Setiawan Temy, and Sugiono Arief. "Fraud Analysis at PT Indofarma Indonesia: A Contextual Qualitative Study using the Fraud Hexagon Model." INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH AND ANALYSIS 08, no. 05 (2025): 2253–58. https://doi.org/10.5281/zenodo.15380382.
Testo completoGlorya Oktavianti, Bernike Trivena N, and Boniface Ata D. "ANALISA LAPORAN KEUANGAN PERUSAHAAN FARMASI TAHUN 2019-2022." Transformasi: Journal of Economics and Business Management 1, no. 4 (2022): 178–92. http://dx.doi.org/10.56444/transformasi.v1i4.279.
Testo completoRidianto, Rini, Ravika Permata Hati, and Hanafi Siregar. "Pengaruh Pertumbuhan Perusahaan, Return On Investment Dan Earning Per Share Terhadap Harga Saham Pada Pt. Kimia Farma Dan Pt. Indofarma Sebelum Dan Selama Pandemi Covid-19." Measurement Jurnal Akuntansi 18, no. 1 (2024): 121–30. http://dx.doi.org/10.33373/mja.v18i1.6436.
Testo completoSaputra, Derian, and Anum Nuryani. "Analisis Financial Distress Menggunakan Metode Altman Z-Score pada PT Indofarma Tbk Periode 2013-2022." AMANAH : Jurnal Ilmiah Ilmu Manajemen 2, no. 2 (2024): 92–108. https://doi.org/10.70451/amanah.v2i2.114.
Testo completoMokoginta, Rena Mustari. "Mengukur Kinerja Keuangan Menggunakan Eva dan Rasio Aktivitas Pada Industri Farmasi Setelah Holding BUMN." ARBITRASE: Journal of Economics and Accounting 4, no. 1 (2023): 23–32. http://dx.doi.org/10.47065/arbitrase.v4i1.1052.
Testo completoHangline Herlistiana, Pratista, MGS Aritonang, and Tedy Herdiana. "The Effect of Production and Sales on Leverage and Profitability in The JKN Era (State-Owned and Private Pharmaceutical Companies Tbk, Period 2014–2018)." Daengku: Journal of Humanities and Social Sciences Innovation 3, no. 4 (2023): 662–75. http://dx.doi.org/10.35877/454ri.daengku1921.
Testo completoLinda, Nur, and Sri Hermuningsih. "ANALISIS KINERJA KEUANGAN SEBELUM DAN SESUDAH PEMBENTUKAN HOLDING BUMN FARMASI PADA PT KIMIA FARMA, Tbk dan PT INDOFARMA, Tbk." CAPITAL: Jurnal Ekonomi dan Manajemen 6, no. 2 (2023): 447. http://dx.doi.org/10.25273/capital.v6i2.14488.
Testo completoSoviatun, Nuria, and Jerry Heikal. "THE CHANGES IN FINANCIAL PERFORMANCE SEGMENTATION USING FINANCIAL RATIOS PHARMACEUTICAL COMPANIES IN INDONESIA." Cerdika: Jurnal Ilmiah Indonesia 3, no. 08 (2023): 828–39. http://dx.doi.org/10.59141/cerdika.v3i08.688.
Testo completoDesmaniar, Salwa Anisya, Listri Herlina, and Ilham Winar Nugroho. "Pengaruh Current Ratio, Debt to Asset Ratio, dan Total Asset Turnover Terhadap Return on Asset Pada PT IndoFarma (INAF) Tbk Periode 2014-2023." Jurnal Ilmu Sosial, Manajemen, Akuntansi dan Bisnis 5, no. 3 (2024): 550–61. http://dx.doi.org/10.47747/jismab.v5i3.1941.
Testo completoManossoh, Hendrik, and Joanne Valesca Mangindaan. "DAMPAK PANDEMI COVID-19 TERHADAP HARGA SAHAM PT. INDOFARMA TBK." JMBI UNSRAT (Jurnal Ilmiah Manajemen Bisnis dan Inovasi Universitas Sam Ratulangi). 10, no. 1 (2023): 539–47. http://dx.doi.org/10.35794/jmbi.v10i1.48182.
Testo completoNoviarty, Helisa, and Yuniarsih Edryani. "DAMPAK PANDEMI COVID-19 TERHADAP PENGUNGKAPAN TANGGUNG JAWAB SOSIAL PADA SEKTOR FARMASI." JAAKFE UNTAN (Jurnal Audit dan Akuntansi Fakultas Ekonomi Universitas Tanjungpura) 10, no. 2 (2021): 11. http://dx.doi.org/10.26418/jaakfe.v10i2.50961.
Testo completoRosa, Sara Nurdia, Ledia Tereza, Efa Agustina, Yulana Desilfa, and Dian Puji Puspita Sari. "Formation of Optimal Portfolio Using A Single Index in Pharmaceutical Companies." Research in Accounting Journal (RAJ) 4, no. 1 (2023): 19–26. https://doi.org/10.37385/raj.v3i1.1892.
Testo completoManungkalit, Santa Maria, Dimas Sumitra Danisworo, and Banter Laksana. "Analisis Rasio Profitabilitas untuk Menilai Kinerja Keuangan PT Indofarma (Persero),Tbk." Indonesian Journal of Economics and Management 2, no. 3 (2022): 621–29. http://dx.doi.org/10.35313/ijem.v2i3.3739.
Testo completoUtami, Ismi Fauzi, and Wuri Widyani Hapsari. "PENERAPAN IDENTITAS VISUAL PERUSAHAAN PT. BIO FARMA (PERSERO) MELALUI DESAIN GRAFIS PADA MEDIA SOSIAL INSTAGRAM." VISWA DESIGN: Journal of Design 3, no. 2 (2023): 122–33. http://dx.doi.org/10.59997/vide.v3i2.1410.
Testo completoMulatsih, Dyah Ajeng, and Irni Yunita. "ANALISIS KINERJA DAN KESEHATAN KEUANGAN PERUSAHAAN PADA INDUSTRI FARMASI DENGAN METODE DU PONT SYSTEM DAN MODEL ALTMAN Z-SCORE." Jurnal Mitra Manajemen 3, no. 1 (2019): 44–56. http://dx.doi.org/10.52160/ejmm.v3i1.178.
Testo completoDevi Savira S and Sri Trisnaningsih. "Violation of Accountant Professional Ethics in the Case of PT. Indofarma Tbk." International Journal of Management Research and Economics 3, no. 1 (2024): 36–45. https://doi.org/10.54066/ijmre-itb.v3i1.2551.
Testo completoFernawati, Amelia Fernawati, and Dhea Lestari Noor Putri. "Analisis Rasio Profitabilitas dan Rasio Aktivitas Sebagai Dasar Penilaian Kinerja Keuangan Pada PT Indofarma (Persero) Tbk Periode Maret 2014-2018." Jurnal Aktiva : Riset Akuntansi dan Keuangan 2, no. 1 (2022): 35–45. http://dx.doi.org/10.52005/aktiva.v2i1.145.
Testo completoOctavianty, Ellyn, and Muhamad Syahrial. "ANALISIS FUNDAMENTAL TERHADAP KINERJA KEUANGAN UNTUK PENGAMBILAN KEPUTUSAN PEMBELIAN SAHAM PADA PERUSAHAAN BUMN YANG TERDAFTAR DI BEI." JIMFE (Jurnal Ilmiah Manajemen Fakultas Ekonomi) 6, no. 1 (2018): 17–25. http://dx.doi.org/10.34203/jimfe.v6i1.468.
Testo completoSofyan Marwansyah, Rani Kurniasari, Teni Agustina, and Nurlaela Eva Puji Lestari. "Analisis Evaluasi Kinerja Portofolio Saham dengan Metode Sharpe pada Perusahaan Farmasi." GEMILANG: Jurnal Manajemen dan Akuntansi 5, no. 2 (2025): 271–82. https://doi.org/10.56910/gemilang.v5i2.1965.
Testo completoDewi, Iriana Kusuma, and Putri Nilam Kencana. "Dampak Pandemi Covid-19 Terhadap Kinerja Perusahaan Farmasi yang terdaftar di BEI." Jurnal Madani: Ilmu Pengetahuan, Teknologi, dan Humaniora 5, no. 1 (2022): 54–67. http://dx.doi.org/10.33753/madani.v5i1.197.
Testo completo., Susilawati, O. Feriyanto, and Dessy Nurlaelasari. "Pengaruh Perputaran Persediaan dan Perputaran Total Aset Terhadap Profitabilitas Pada PT Indofarma (Persero) Tbk." STAR 14, no. 1 (2022): 22. http://dx.doi.org/10.55916/jsar.v14i1.33.
Testo completoMadewi, Astuti. "ANALISIS PREDIKSI KEBANGKRUTAN MENGGUNAKAN MODEL ALTMAN Z-SCORE PT. INDOFARMA TBK TAHUN 2020-2022." ECONOMIST: Jurnal Ekonomi dan Bisnis 1, no. 3 (2024): 12–21. https://doi.org/10.63545/economist.v1i3.26.
Testo completoWahyuni, Liza, and Charoline Cheisviyanny. "Analisis Praktik Corporate Social Responsibility (CSR) Saat Pandemi Covid-19 pada Perusahaan Farmasi." JURNAL EKSPLORASI AKUNTANSI 5, no. 3 (2023): 1065–83. http://dx.doi.org/10.24036/jea.v5i3.794.
Testo completoRohmah, Siti, Erni Setawati, Pantas P. Pardede, and Mutiara Rahman. "DETERMINAN DETEKSI KECURANGAN LAPORAN KEUANGAN." Jurnal GeoEkonomi 15, no. 1.2024 (2024): 131–40. http://dx.doi.org/10.36277/geoekonomi.v15i1.2024.440.
Testo completoRahmawati, Ira, and Dini Verdania Latif. "Pengaruh Total Aset Turnover (Tato) Dan Return On Equity(Roe) Terhadap Pertumbuhan Laba (Studi Kasus Pada Perusahaan Sektor Farmasi Yang Terdaftar Di Bursa Efek Indonesia Selama Masa Pandemi Covid -19)." Journal of Economic, Bussines and Accounting (COSTING) 6, no. 2 (2023): 1886–95. http://dx.doi.org/10.31539/costing.v6i2.5371.
Testo completoFernawati, Amelia Fernawati. "Analisis Rasio Profitabilitas dan Rasio Keuangan Sebagai Dasar Penilaian Kinerja Keuangan Pada PT. Indofarma (Persero) Tbk Periode Maret 2014-2018." Jurnal Aktiva : Riset Akuntansi dan Keuangan 1, no. 3 (2020): 35–45. http://dx.doi.org/10.52005/aktiva.v2i1.50.
Testo completoHairani, Yuniar Is, and Isnawati Isnawati. "DETERMINAN POTENSI KECURANGAN LAPORAN KEUANGAN DI INDONESIA." Jurnal Riset Akuntansi Aksioma 23, no. 1 (2024): 1–21. http://dx.doi.org/10.29303/aksioma.v23i1.267.
Testo completoRambe, Muhammad Juang, Wahyu Indah Sari, and Danioko S. Sembiring. "The position of state-owned enterprises: Towards a health sector super holding company paradigm." Proceeding of International Conference on Healthy Living (INCOHELIV) 1, no. 1 (2024): 315–22. http://dx.doi.org/10.24123/incoheliv.v1i1.6586.
Testo completoAbdurrahman, Abdurrahman, and Aris Munandar. "ANALISIS RASIO KEUANGAN UNTUK MENILAI KINERJA KEUANGAN PERUSAHAAN FARMASI PT. INDOFARMA, Tbk TAHUN 2011 – 2018." MOTIVASI 5, no. 2 (2020): 860. https://doi.org/10.32502/mti.v5i2.2824.
Testo completoUriawan, Wisnu, and Iwan Permana. "Effect of Return on Assets (ROA) and Leverage Ratio on Company Value of PT. MNC Land Tbk." Journal of Islamic Economics and Business 2, no. 2 (2023): 152–69. http://dx.doi.org/10.15575/jieb.v2i2.22425.
Testo completoPutri, Berlian Ernita, Nella Yantiana, and Angga Permadi Karpriana. "Penerapan Model Grover dalam Memprediksi Kebangkrutan pada Sektor Farmasi yang Terdaftar di Bursa Efek Indonesia." Manajemen & Bisnis Jurnal 10, no. 2 (2024): 42–54. https://doi.org/10.37303/embeji.v10i2.214.
Testo completo